Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature.
OBJECTIVE: Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19.
METHODS: IDSA formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations.
RESULTS: The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations.
CONCLUSIONS: The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.
| Errataetall: |
CommentIn: Clin Infect Dis. 2020 Nov 19;71(16):2298-2299. - PMID 32337537 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - (2020) vom: 27. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bhimraj, Adarsh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Print-Electronic CommentIn: Clin Infect Dis. 2020 Nov 19;71(16):2298-2299. - PMID 32337537 Citation Status Publisher |
|---|
| doi: |
10.1093/cid/ciaa478 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309227844 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309227844 | ||
| 003 | DE-627 | ||
| 005 | 20240229162805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa478 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1308.xml |
| 035 | |a (DE-627)NLM309227844 | ||
| 035 | |a (NLM)32338708 | ||
| 035 | |a (PII)ciaa478 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bhimraj, Adarsh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Infect Dis. 2020 Nov 19;71(16):2298-2299. - PMID 32337537 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature | ||
| 520 | |a OBJECTIVE: Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19 | ||
| 520 | |a METHODS: IDSA formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations | ||
| 520 | |a RESULTS: The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations | ||
| 520 | |a CONCLUSIONS: The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Morgan, Rebecca L |e verfasserin |4 aut | |
| 700 | 1 | |a Shumaker, Amy Hirsch |e verfasserin |4 aut | |
| 700 | 1 | |a Lavergne, Valery |e verfasserin |4 aut | |
| 700 | 1 | |a Baden, Lindsey |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Vincent Chi-Chung |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Kathryn M |e verfasserin |4 aut | |
| 700 | 1 | |a Gandhi, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Muller, William J |e verfasserin |4 aut | |
| 700 | 1 | |a O'Horo, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Shoham, Shmuel |e verfasserin |4 aut | |
| 700 | 1 | |a Murad, M Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Mustafa, Reem A |e verfasserin |4 aut | |
| 700 | 1 | |a Sultan, Shahnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Falck-Ytter, Yngve |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g (2020) vom: 27. Apr. |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:27 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa478 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 27 |c 04 | ||